TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells

TRAIL induces apoptosis in cancer cells whilst sparing normal tissues. Despite promising pre-clinical results, few patients responded to treatment with recombinant TRAIL (Apo2L/Dulanermin) or TRAIL-R2-specific antibodies, such as conatumumab (AMG655). It is unknown whether this was due to intrinsic...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncogene
Asıl Yazarlar: Tuthill, Mark H, Montinaro, Antonella, Zinngrebe, Julia, Prieske, Katharina, Draber, Peter, Prieske, Stefan, Newsom-Davis, Tom, von Karstedt, Silvia, Graves, Jonathan, Walczak, Henning
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4240732/
https://ncbi.nlm.nih.gov/pubmed/24909167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2014.156
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller